Servier India Launches Ivosidenib for AML and Cholangiocarcinoma Patients with IDH1 Mutation Following CDSCO Approval

Servier India has introduced Ivosidenib, a targeted therapy for patients with acute myeloid leukemia (AML) and cholangiocarcinoma who exhibit the IDH1 mutation. The therapy received approval from the Central Drugs Standard Control Organisation (CDSCO), marking its availability for use in India.

Ivosidenib is designed to address specific genetic mutations associated with AML and cholangiocarcinoma, offering a treatment option for individuals whose conditions are linked to the IDH1 mutation. The approval by CDSCO signifies that the drug meets regulatory standards for safety and efficacy within these patient groups. This development provides healthcare professionals with an additional tool in managing these challenging diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Biopharmaceutical Companies Employ Advanced Tools and Expertise for Freedom to Operate Analysis to Navigate Intellectual Property Rights Daylight Exposure Linked to Enhanced Immune System Function in Fighting Infections FDA Updates Section 804 to Streamline Importation of Prescription Drugs from Canada Inflation Reduction Act to Introduce New Barriers for Medicare Patients in Immunology, Oncology, and Endocrinology by 2025

Author

Mark Chiang